石四藥集團(02005.HK):頭孢地尼膠囊及琥珀酸普蘆卡必利片中標第三批集採
格隆匯8月21日丨石四藥集團(02005.HK)宣佈,集團新產品頭孢地尼膠囊及琥珀酸普蘆卡必利片於2020年8月20日的中國全國藥品集中採購招標中均以第一順位中標。集團於2020年7月獲得頭孢地尼膠囊及琥珀酸普蘆卡必利片的藥品生產註冊批件。
根據全國藥品集中採購招標安排,集團頭孢地尼膠囊將獨家供應江蘇、浙江、湖北、安徽、遼寧、河北、甘肅、山西和青海共9個省份,而琥珀酸普蘆卡必利片將將獨家供應廣東、江蘇、湖北、遼寧、上海、陝西、江西、雲南、寧夏、甘肅和青海共11個省份。
董事局預期是次中標將有利相關新產品迅速開發市場,形成規模銷售,提高市場佔有率,對集團未來銷售帶來正面的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.